z-logo
Premium
Pharmacokinetics of Single and Repeat Doses of Fluticasone Furoate/Umeclidinium/Vilanterol in Healthy Chinese Adults
Author(s) -
Li Yan,
Li Huafang,
Sheng Yucheng,
Du Xin,
Yao Yuhui,
Luo Xian,
Ma Peiming
Publication year - 2018
Publication title -
clinical pharmacology in drug development
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.711
H-Index - 22
eISSN - 2160-7648
pISSN - 2160-763X
DOI - 10.1002/cpdd.626
Subject(s) - fluticasone propionate , medicine , pharmacokinetics , dry powder inhaler , cmax , pharmacology , dosing , area under the curve , zoology , inhaler , corticosteroid , asthma , biology
Abstract The pharmacokinetics (PK) and safety of single‐inhaler fluticasone furoate/umeclidinium/vilanterol (FF/UMEC/VI) after single and repeat dosing in healthy Chinese adults were assessed. In this open‐label study (NCT02837380), subjects received once‐daily FF/UMEC/VI 100/62.5/25 µg on day 1 and repeat doses on days 2–7. PK parameters (days 1 and 7) included maximum observed concentration (C max ) and area under the plasma concentration‐time curve (AUC) from time zero (predose) to last time of quantifiable concentration (AUC 0–t ). Terminal phase half‐life (t ½ ) on day 1 was estimated. The primary objective was to assess systemic exposure of FF 100 µg, UMEC 62.5 µg, and VI 25 µg following single‐inhaler triple therapy on days 1 and 7. On day 1, geometric mean t ½ of UMEC and VI was 0.36 and 0.52 hours, respectively; t ½ of FF was not representative because of nonquantifiable concentration data. On days 1 and 7, geometric mean C max of FF was 10.46 and 27.32 pg/mL, respectively; C max of UMEC was 144.14 and 241.35 pg/mL, respectively; and C max of VI was 120.42 and 196.78 pg/mL, respectively. AUC 0–t of FF was 1.77 and 276.96 pg·h/mL, respectively; AUC 0–t of UMEC was 28.44 and 117.19 pg·h/mL, respectively; and AUC 0–t of VI, 42.46 and 101.12 pg·h/mL, respectively. The PK of FF/UMEC/VI was as expected for the individual‐component PK previously reported in healthy Chinese adults. No new safety signals were observed.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here